ClinicalTrials.gg
CompletedNCT04872101DELTA 2Updated Apr 8, 2025Results posted

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)

A Phase 3 interventional study of Delgocitinib cream and Cream vehicle in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
473
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
4th of 12
473 · median 178
Started
2021
with 2 others
Phase 3
7 of 13
none open now
Registered
6th of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 3, and was the 6th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

This was a 16-week study in adult participants with chronic hand eczema (CHE). The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life.

The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance.

03

Conditions studied

  • Chronic Hand Eczema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  • Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
  • Disease severity graded as moderate to severe at screening and baseline according to Investigator's Global Assessment for chronic hand eczema (IGA-CHE) (i.e. an IGA-CHE score of 3 or 4).
  • Hand Eczema Symptom Diary (HESD) itch score (weekly average) of ≥4 points at baseline.
  • Participants who have a documented recent history of inadequate response to treatment with topical (TCS) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
  • Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.

Main exclusion criteria:

  • Concurrent skin diseases on the hands, e.g. tinea manuum.
  • Active atopic dermatitis requiring medical treatment in regions other than the hands and feet.
  • Active psoriasis on any part of the body.
  • Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
  • infection on the hands.
  • Systemic treatment with drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline.
  • Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline.
  • Previous or current treatment with Janus kinase (JAK) inhibitors (including delgocitinib/LEO 124249), systemic or topical.
  • Cutaneously applied treatment with immunomodulators or TCS on the hands within 14 days prior to baseline.
  • Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
  • Other transdermal or cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline.
  • Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
  • Treatment with any marketed biological therapy or biologic agents:

    • Any cell-depleting agents: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
    • Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
  • Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial.
  • History of any known primary immunodeficiency disorder including a positive (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
  • Any disorder which is not stable and could:

    • Affect the safety of the participant throughout the trial.
    • Impede the participant's ability to complete the trial.
  • Positive surface antigen or virus antibody serology at screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
473 participants (actual)

Study arms

  • Experimental
    Delgocitinib cream 20 mg/g

    Twice-daily topical application for 16 weeks

    Drug: Delgocitinib cream

  • Placebo comparator
    Cream vehicle

    Twice-daily topical application for 16 weeks

    Drug: Cream vehicle

Interventions

  • Cream for topical application

    Also known as: LEO 124249 cream

  • DrugCream vehicle

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

06

What researchers measure

Primary outcomes

  1. Number of Participants With IGA-CHE TS at Week 16

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

    Time frame: 16 weeks

Secondary outcomes

  1. Number of Participants With IGA-CHE TS at Week 8

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

    Time frame: 8 weeks

  2. Number of Participants With IGA-CHE TS at Week 4

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

    Time frame: 4 weeks

  3. Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.

    Time frame: 16 weeks

  4. Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. The HESD score is derived as the average of the 6 signs and symptoms. This endpoint will be evaluated among participants with a baseline HESD score (weekly average) ≥4 points.

    Time frame: 16 weeks

  5. Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 8

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.

    Time frame: 8 weeks

  6. Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 4

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.

    Time frame: 4 weeks

  7. Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 2

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.

    Time frame: 2 weeks

  8. Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 8

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. The HESD score is derived as the average of the 6 signs and symptoms. This endpoint will be evaluated among participants with a baseline HESD score (weekly average) ≥4 points.

    Time frame: 8 weeks

  9. Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 4

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. The HESD score is derived as the average of the 6 signs and symptoms. This endpoint will be evaluated among participants with a baseline HESD score (weekly average) ≥4 points.

    Time frame: 4 weeks

  10. Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component and will be evaluated among participants with a baseline HESD pain score (weekly average) ≥4 points.

    Time frame: 16 weeks

  11. Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 8

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component and will be evaluated among participants with a baseline HESD pain score (weekly average) ≥4 points.

    Time frame: 8 weeks

  12. Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 4

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component and will be evaluated among participants with a baseline HESD pain score (weekly average) ≥4 points.

    Time frame: 4 weeks

  13. Number of Participants With HECSI-90 at Week 16

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.

    Time frame: 16 weeks

  14. Number of Participants With HECSI-75 at Week 16

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-75 is defined as at least 75% improvement in HECSI score from baseline.

    Time frame: 16 weeks

  15. Number of Participants With HECSI-75 at Week 8

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-75 is defined as at least 75% improvement in HECSI score from baseline.

    Time frame: 8 weeks

  16. Percentage Change in HECSI Score From Baseline to Week 16

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity.

    Time frame: 16 weeks

  17. Change in DLQI Score From Baseline to Week 16

    The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life.

    Time frame: 16 weeks

  18. Change in HESD Score (Weekly Average) From Baseline to Week 16

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. The HESD score is derived as the average of the 6 signs and symptoms.

    Time frame: 16 weeks

  19. Change in HESD Itch Score (Weekly Average) From Baseline to Week 16

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.

    Time frame: 16 weeks

  20. Change in HESD Pain Score (Weekly Average) From Baseline to Week 16

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.

    Time frame: 16 weeks

  21. Change in HEIS Score From Baseline to Week 16

    The Hand Eczema Impact Scale (HEIS) addresses 9 items within the following domains: Proximal Daily Activity Limitations (PDAL), embarrassment with the appearance of the hands, frustration with CHE, sleep, work, and physical functioning. Each item is scored on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The HEIS score is the average of the 9 items.

    Time frame: 16 weeks

  22. Change in HEIS PDAL Score From Baseline to Week 16

    Proximal Daily Activity Limitations (PDAL) is one of the items addressed in the Hand Eczema Impact Scale (HEIS) and is scored on a 5-point scale ranging from 0 (not at all) to 4 (extremely).

    Time frame: 16 weeks

  23. Number of Participants With Reduction of DLQI Score of ≥4 Points From Baseline at Week 16

    The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life. This endpoint will be evaluated among participants with a baseline DLQI score ≥4 points.

    Time frame: 16 weeks

  24. Number of Treatment-emergent AEs From Baseline up to End of Trial

    An adverse event (AE) were considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP. End of trial was defined as Week 16 for participants who rolled over to the long-term extension trial and as Week 18 for participants who did not roll over.

    Time frame: 16 weeks (18 weeks for participants not participating in the long-term extension trial [LP0133-1403])

07

Results

Posted Oct 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneDelgocitinib Cream 20 mg/gCream Vehicle
Started314159
Completed291122
Not completed2337
Withdrew: Withdrawal by subject1016
Withdrew: Lack of efficacy614
Withdrew: Adverse event16
Withdrew: Lost to follow-up21
Withdrew: Pregnancy20
Withdrew: Prohibited medication10
Withdrew: Not dosed10

Outcome measures

PrimaryNumber of Participants With IGA-CHE TS at Week 16

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE TS at Week 16
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With IGA-CHE TS at Week 169111
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (5% significance level (two-sided).) · Risk difference (rd): 22.2 · 95% CI 15.8 to 28.5Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With IGA-CHE TS at Week 8

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE TS at Week 8
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With IGA-CHE TS at Week 810115
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 22.9 · 95% CI 16.0 to 29.8Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With IGA-CHE TS at Week 4

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE TS at Week 4
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With IGA-CHE TS at Week 44613
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = 0.043 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 6.5 · 95% CI 0.8 to 12.3Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 1614631
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided).) · Risk difference (rd): 27.4 · 95% CI 19.0 to 35.8Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. The HESD score is derived as the average of the 6 signs and symptoms. This endpoint will be evaluated among participants with a baseline HESD score (weekly average) ≥4 points.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 1613732
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 23.7 · 95% CI 15.1 to 32.2Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 8

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 8
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 813121
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 29.0 · 95% CI 21.3 to 36.7Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 4

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 4
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 49419
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 18.3 · 95% CI 11.0 to 25.6Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 2

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.

Time frame:
2 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 2
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 24010
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = 0.031 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 6.6 · 95% CI 1.1 to 12.0Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 8

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. The HESD score is derived as the average of the 6 signs and symptoms. This endpoint will be evaluated among participants with a baseline HESD score (weekly average) ≥4 points.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 8
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 811519
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 25.0 · 95% CI 17.5 to 32.5Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 4

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. The HESD score is derived as the average of the 6 signs and symptoms. This endpoint will be evaluated among participants with a baseline HESD score (weekly average) ≥4 points.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 4
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 48014
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 16.9 · 95% CI 10.2 to 23.7Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component and will be evaluated among participants with a baseline HESD pain score (weekly average) ≥4 points.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 1614332
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 26.0 · 95% CI 17.0 to 35.1Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 8

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component and will be evaluated among participants with a baseline HESD pain score (weekly average) ≥4 points.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 8
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 812418
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 29.6 · 95% CI 21.7 to 37.4Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 4

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component and will be evaluated among participants with a baseline HESD pain score (weekly average) ≥4 points.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 4
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 49115
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 5% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 20.5 · 95% CI 13.1 to 27.8Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With HECSI-90 at Week 16

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With HECSI-90 at Week 16
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With HECSI-90 at Week 169714
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 22.2 · 95% CI 15.4 to 29.0Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With HECSI-75 at Week 16

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-75 is defined as at least 75% improvement in HECSI score from baseline.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With HECSI-75 at Week 16
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With HECSI-75 at Week 1615529
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 31.3 · 95% CI 23.1 to 39.5Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Participants With HECSI-75 at Week 8

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-75 is defined as at least 75% improvement in HECSI score from baseline.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Participants With HECSI-75 at Week 8
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With HECSI-75 at Week 815831
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 31.0 · 95% CI 22.7 to 39.3Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryPercentage Change in HECSI Score From Baseline to Week 16

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity.

Time frame:
16 weeks
Reported as:
Least squares mean · percentage change
Percentage Change in HECSI Score From Baseline to Week 16
percentage changeDelgocitinib Cream 20 mg/gCream Vehicle
Percentage Change in HECSI Score From Baseline to Week 16-58.9 ± 3.2-13.4 ± 4.5
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · ANCOVA · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Mean difference (net): -45.5 · 95% CI -56.4 to -34.6Adjusted for treatment, region, baseline IGA-CHE score, and baseline HECSI score.
SecondaryChange in DLQI Score From Baseline to Week 16

The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life.

Time frame:
16 weeks
Reported as:
Least squares mean · score on a scale
Change in DLQI Score From Baseline to Week 16
score on a scaleDelgocitinib Cream 20 mg/gCream Vehicle
Change in DLQI Score From Baseline to Week 16-7.0 ± 0.3-3.1 ± 0.5
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · ANCOVA · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Mean difference (net): -3.9 · 95% CI -5.0 to -2.8Adjusted for treatment, region, baseline IGA-CHE score, and baseline DLQI score.
SecondaryChange in HESD Score (Weekly Average) From Baseline to Week 16

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. The HESD score is derived as the average of the 6 signs and symptoms.

Time frame:
16 weeks
Reported as:
Least squares mean · score on a scale
Change in HESD Score (Weekly Average) From Baseline to Week 16
score on a scaleDelgocitinib Cream 20 mg/gCream Vehicle
Change in HESD Score (Weekly Average) From Baseline to Week 16-3.2 ± 0.1-1.4 ± 0.2
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · ANCOVA · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Mean difference (net): -1.9 · 95% CI -2.4 to -1.4Adjusted for treatment, region, baseline IGA-CHE score, and baseline HESD score.
SecondaryChange in HESD Itch Score (Weekly Average) From Baseline to Week 16

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.

Time frame:
16 weeks
Reported as:
Least squares mean · score on a scale
Change in HESD Itch Score (Weekly Average) From Baseline to Week 16
score on a scaleDelgocitinib Cream 20 mg/gCream Vehicle
Change in HESD Itch Score (Weekly Average) From Baseline to Week 16-3.4 ± 0.2-1.4 ± 0.2
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · ANCOVA · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Median difference (net): -2.0 · 95% CI -2.5 to -1.4Adjusted for treatment, region, baseline IGA-CHE score, and baseline HESD itch score.
SecondaryChange in HESD Pain Score (Weekly Average) From Baseline to Week 16

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.

Time frame:
16 weeks
Reported as:
Least squares mean · score on a scale
Change in HESD Pain Score (Weekly Average) From Baseline to Week 16
score on a scaleDelgocitinib Cream 20 mg/gCream Vehicle
Change in HESD Pain Score (Weekly Average) From Baseline to Week 16-3.3 ± 0.2-1.3 ± 0.2
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · ANCOVA · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Mean difference (net): -2.0 · 95% CI -2.6 to -1.5Adjusted for treatment, region, baseline IGA-CHE score, and baseline HESD pain score.
SecondaryChange in HEIS Score From Baseline to Week 16

The Hand Eczema Impact Scale (HEIS) addresses 9 items within the following domains: Proximal Daily Activity Limitations (PDAL), embarrassment with the appearance of the hands, frustration with CHE, sleep, work, and physical functioning. Each item is scored on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The HEIS score is the average of the 9 items.

Time frame:
16 weeks
Reported as:
Least squares mean · score on a scale
Change in HEIS Score From Baseline to Week 16
score on a scaleDelgocitinib Cream 20 mg/gCream Vehicle
Change in HEIS Score From Baseline to Week 16-1.45 ± 0.06-0.64 ± 0.08
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · ANCOVA · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Median difference (net): -0.81 · 95% CI -0.99 to -0.62Adjusted for treatment, region, baseline IGA-CHE score, and baseline HEIS score.
SecondaryChange in HEIS PDAL Score From Baseline to Week 16

Proximal Daily Activity Limitations (PDAL) is one of the items addressed in the Hand Eczema Impact Scale (HEIS) and is scored on a 5-point scale ranging from 0 (not at all) to 4 (extremely).

Time frame:
16 weeks
Reported as:
Least squares mean · score on a scale
Change in HEIS PDAL Score From Baseline to Week 16
score on a scaleDelgocitinib Cream 20 mg/gCream Vehicle
Change in HEIS PDAL Score From Baseline to Week 16-1.48 ± 0.06-0.66 ± 0.08
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · ANCOVA · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Mean difference (net): -0.82 · 95% CI -1.01 to -0.62Adjusted for treatment, region, baseline IGA-CHE score, and baseline HEIS PDAL score.
SecondaryNumber of Participants With Reduction of DLQI Score of ≥4 Points From Baseline at Week 16

The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life. This endpoint will be evaluated among participants with a baseline DLQI score ≥4 points.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction of DLQI Score of ≥4 Points From Baseline at Week 16
ParticipantsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Participants With Reduction of DLQI Score of ≥4 Points From Baseline at Week 1621670
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (Evaluated at a 1% significance level (two-sided) using hierarchical tests, alpha splitting, and alpha recycling to control overall type 1 error at 5% (two-sided)) · Risk difference (rd): 26.4 · 95% CI 17.0 to 35.9Mantel-Haenszel risk difference, stratified by region and baseline IGA-CHE score.
SecondaryNumber of Treatment-emergent AEs From Baseline up to End of Trial

An adverse event (AE) were considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP. End of trial was defined as Week 16 for participants who rolled over to the long-term extension trial and as Week 18 for participants who did not roll over.

Time frame:
16 weeks (18 weeks for participants not participating in the long-term extension trial [LP0133-1403])
Reported as:
Number · Adverse events
Number of Treatment-emergent AEs From Baseline up to End of Trial
Adverse eventsDelgocitinib Cream 20 mg/gCream Vehicle
Number of Treatment-emergent AEs From Baseline up to End of Trial269145

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Delgocitinib |20 mg/g0/313 (0%)5/313 (1.6%)70/313 (22.4%)
Vehicle|0/159 (0%)3/159 (1.9%)43/159 (27%)
Most frequent serious events
Most frequent serious events
EventDelgocitinib |20 mg/gVehicle|
Cardiac tamponadeCardiac disorders0/3131/159
Notalgia paraestheticaNervous system disorders0/3131/159
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/3131/159
Hand dermatitisSkin and subcutaneous tissue disorders1/3131/159
COVID-19 pneumoniaInfections and infestations1/3130/159
Peritonsillar abscessInfections and infestations1/3130/159
EpilepsyNervous system disorders1/3130/159
MigraineNervous system disorders1/3130/159
Most frequent other events
Most frequent other events
EventDelgocitinib |20 mg/gVehicle|
COVID-19Infections and infestations36/31320/159
NasopharyngitisInfections and infestations21/31310/159
HeadacheNervous system disorders19/3139/159
PharyngitisInfections and infestations3/3135/159
Hand dermatitisSkin and subcutaneous tissue disorders2/3135/159
Herpes simplexInfections and infestations1/3134/159

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Delgocitinib Cream 20 mg/gCream VehicleTotal
<=18 years000
Between 18 and 65 years286150436
>=65 years28937
Age, Continuous
Age, Continuous(years)Delgocitinib Cream 20 mg/gCream VehicleTotal
Mean45.3 ± 14.642.6 ± 14.344.4 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Delgocitinib Cream 20 mg/gCream VehicleTotal
Female204108312
Male11051161
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delgocitinib Cream 20 mg/gCream VehicleTotal
Hispanic or Latino257
Not Hispanic or Latino310152462
Unknown or Not Reported224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Delgocitinib Cream 20 mg/gCream VehicleTotal
American Indian or Alaska Native000
Asian8715
Native Hawaiian or Other Pacific Islander101
Black or African American213
White295146441
More than one race134
Unknown or Not Reported729
Region of Enrollment
Region of Enrollment(participants)Delgocitinib Cream 20 mg/gCream VehicleTotal
Canada643397
Netherlands131124
Belgium111122
Poland643296
Denmark19322
Germany9849147
Spain452065
Baseline IGA-CHE score
Baseline IGA-CHE score(Participants)Delgocitinib Cream 20 mg/gCream VehicleTotal
0 - Clear000
1 - Almost clear000
2 - Mild000
3 - Moderate239121360
4 - Severe7538113
Baseline HECSI score
Baseline HECSI score(units on a scale)Delgocitinib Cream 20 mg/gCream VehicleTotal
Mean64.3 ± 37.967.7 ± 39.565.5 ± 38.5

6 further baseline measures are reported on the registry.

08

Study locations

50 sites
  • LEO Investigational Site
    Brussels, 1000, Belgium
  • LEO Investigational Site
    Edegem, 2650, Belgium
  • LEO Investigational Site
    Gent, 9000, Belgium
  • LEO Investigational Site
    Kortrijk, 8500, Belgium
  • LEO Investigational Site
    Leuven, 3000, Belgium
  • LEO Investigational Site
    Loverval, 6280, Belgium
  • LEO Investigational Site
    Maldegem, 9990, Belgium
  • LEO Investigational Site
    Surrey, British Columbia V3R 6A7, Canada
  • LEO Investigational Site
    Vancouver, British Columbia V6H4E1, Canada
  • LEO Investigational Site
    Fredericton, New Brunswick E3B 1G9, Canada
  • LEO Investigational Site
    Ajax, Ontario L1S 7K8, Canada
  • LEO Investigational Site
    Cobourg, Ontario K9A 4J9, Canada
  • LEO Investigational Site
    Etobicoke, Ontario M8X 1Y9, Canada
  • LEO Investigational Site
    Hamilton, Ontario L8S 1G5, Canada
  • LEO Investigational Site
    Toronto, Ontario M2M 4J5, Canada
  • LEO Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • LEO Investigational Site
    Windsor, Ontario N8W 1E6, Canada
  • LEO Investigational Site
    Copenhagen, 2400, Denmark
  • LEO Investigational Site
    Hellerup, 2900, Denmark
  • LEO Investigational Site
    Århus, 8200, Denmark
  • LEO Investigational Site
    Aachen, 52074, Germany
  • LEO Investigational Site
    Bad Bentheim, 48455, Germany
  • LEO Investigational Site
    Frankfurt, 60590, Germany
  • LEO Investigational Site
    Friedrichshafen, 88045, Germany
  • LEO Invesitgational Site
    Hannover, 30159, Germany
  • LEO Investigational Site
    Jena, 07743, Germany
  • LEO Investigational Site
    Lübeck, 23538, Germany
  • LEO Investigational Site
    Mahlow, 15831, Germany
  • LEO Investigational Site
    Münster, 48149, Germany
  • LEO Investigational Site
    Stuttgart, 70178, Germany
  • LEO Investigational Site
    Amsterdam, 1105 AZ, Netherlands
  • LEO Investigational Site
    Bergen Op Zoom, 4614 VT, Netherlands
  • LEO Investigational Site
    Breda, 4818 CK, Netherlands
  • LEO Investigational Site
    Groningen, 9713 GZ, Netherlands
  • LEO Investigational Site
    Hoofddorp, 2134 TM, Netherlands
  • LEO Investigational Site
    Utrecht, 3584 CX, Netherlands
  • LEO Investigational Site
    Białystok, 15-375, Poland
  • LEO Investigational Site
    Lublin, 20-406, Poland
  • LEO Investigational Site
    Rzeszow, 35-055, Poland
  • LEO Investigational Site
    Warszawa, 02-625, Poland
  • LEO Investigational Site
    Warszawa, 02-962, Poland
  • LEO Investigational Site
    Wroclaw, 50-566, Poland
  • LEO Investigational Site
    Wroclaw, 51-318, Poland
  • LEO Investigational Site
    Mieres, Asturias 33611, Spain
  • LEO Investigational Site
    Badalona, Barcelona 08915, Spain
  • LEO Investigational Site
    Bilbao, Vizcaya 48013, Spain
  • LEO Investigational Site
    Alicante, 03010, Spain
  • LEO Investigational Site
    Barcelona, 08041, Spain
  • LEO Investigational Site
    Madrid, 28031, Spain
  • LEO Investigational Site
    Sevilla, 41009, Spain
09

References and documents

Publications

  • Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crepy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18. PubMed 39033766 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2022, 19 months.

Results were first posted in Oct 2024, 1 year 9 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 71 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
May 4, 2021
StartActual
May 25, 2021
Primary completionActual
Dec 27, 2022
CompletionActual
Jan 6, 2023
Results first posted
Oct 17, 2024
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04872101
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
May 4, 2021
Start date
May 25, 2021
Primary completion
Dec 27, 2022
Completion
Jan 6, 2023
Results posted
Oct 17, 2024
Last update
Apr 8, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion